Erythrocyte Patents (Class 435/7.25)
  • Patent number: 10107811
    Abstract: Methods for detecting the presence or absence of, and for quantifying, one set of cells in a mixed cell population of at least two sets of cells especially Rh positive cells in a mixed population with Rh negative cells, as is found in a fetal maternal hemorrhage (FMH). The magnetic particles coated with anti-D antibodies are reacted with the Rh positive fetal cells in Rh negative maternal blood followed by a specific separation and quantifying technique. Gravitational forces or magnetic forces are used to move reacted magnetic particles to isolate, distinguish and quantify cells differentiated by antigenic composition. Rh positive cell volume is correlated to the volume of the original blood sample as an indication of the number of doses of RhIG needed to be administered to the mother to prevent subsequent Rh immunization.
    Type: Grant
    Filed: November 4, 2015
    Date of Patent: October 23, 2018
    Assignee: Chrome Red Technologies, LLC
    Inventors: Henry A. Graham, John G. Gorman, James P. Rowell
  • Patent number: 10054593
    Abstract: New methods and assays for multiplexed detection of analytes using phosphors that are uniform in morphology, size, and composition based on their unique optical lifetime signatures are described herein. The described assays and methods can be used for imaging or detection of multiple unique chemical or biological markers simultaneously in a single assay readout.
    Type: Grant
    Filed: June 6, 2016
    Date of Patent: August 21, 2018
    Assignees: INTELLEIGENT MATERIAL SOLUTIONS, INC., LEIDEN UNIVERSITY MEDICAL CENTER, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES
    Inventors: Howard Y. Bell, Joshua E. Collins, Paul L. A. M. Corstjens, Sukwan Handali, Hans J. Tanke
  • Patent number: 9915657
    Abstract: Fungal infections are difficult to diagnose. The most common filamentous fungal infection, aspergillosis, carries with it a high mortality. Culture of the organism is difficult and obtaining samples, e.g., through a lung biopsy, sometimes causes morbidity. Biomarkers that indicate ‘early’ infection in it development are sought after. One such biomarker is detection of galactomannan (GM), a polysaccharide that is attached to hyphal cell walls and secreted during growth of the organism. Galactomannan is excreted in urine. Disclosed herein is a lateral flow assay comprising monoclonal antibodies that recognize specific residues of Aspergillus fumigatus for detecting GM in urine samples to provide a point-of-care detection device to allow for frequent screening and early diagnosis in patients at high risk for infection.
    Type: Grant
    Filed: November 18, 2014
    Date of Patent: March 13, 2018
    Assignees: YESHIVA UNIVERSTIY, THE JOHNS HOPKINS UNIVERSITY
    Inventors: Kieren A. Marr, Marta Feldmesser, Janet F. Staab
  • Patent number: 9911938
    Abstract: In a method of manufacturing a quantum dot, a core may be formed using (utilizing) at least one cation precursor and at least one anion precursor. The core may be reacted with a shell forming precursor and a ligand forming precursor for more than one hour to form a shell enclosing the core and a ligand. A nanoparticle including the core, the shell and the ligand may be washed.
    Type: Grant
    Filed: January 25, 2017
    Date of Patent: March 6, 2018
    Assignees: Samsung Display Co., Ltd., Industry-Academia Cooperation Foundation, Hongik University
    Inventors: Hee-Joo Ko, Hee-Sun Yang, Ki-Heon Lee, Jeong-Hoon Lee, Chang-Ho Lee
  • Patent number: 9629933
    Abstract: Erythrocytes exposed to dialysis with an hypotonic buffer stably take up superparamagnetic iron oxide nanoparticles and may be used MRI contrast agents. Such erythrocytes may also be used as drug delivery vehicles.
    Type: Grant
    Filed: July 3, 2007
    Date of Patent: April 25, 2017
    Assignee: Erydel S.P.A.
    Inventors: Mauro Magnani, Antonella Antonelli
  • Patent number: 9518983
    Abstract: The present invention relates to a method for purifying biomolecules or for analyzing whether an aqueous phase contains biomolecules by means of magnetic separation. The invention further relates to uses, to devices, and to kits that relate to the method according to the invention.
    Type: Grant
    Filed: March 25, 2010
    Date of Patent: December 13, 2016
    Assignee: QIAGEN, GmbH
    Inventor: Janina Cramer
  • Patent number: 9474810
    Abstract: The present application discloses nanoparticles, particularly nanoparticles of superparamagnetic iron oxide, which find utility in iron therapy and diagnostic imaging such as magnetic resonance (MR). The disclosed nanoparticles have been treated with an ?-hydroxyphosphonic acid conjugate containing polyethylene glycol as a hydrophilic moiety to render the nanoparticles sufficiently hydrophilic to find utility in diagnostic imaging. Among the modified hydrophilic nanoparticles disclosed are those in which the hydrophilic moieties of the modifying conjugate are polyethylene oxide-based polymers and have a molecular weight greater than 5,000 dalton and less than or equal to about 30,000 daltons. Surprisingly, these nanoparticles have a more rapid and complete processing in liver of retained nanoparticles when compared to similar nanoparticles in which the PEG-based hydrophilic moiety has a molecular weight less than 5,000.
    Type: Grant
    Filed: March 2, 2012
    Date of Patent: October 25, 2016
    Assignee: General Electric Company
    Inventors: Bruce Allan Hay, Daniel Eugene Meyer, Brian Christopher Bales, Michael Todd Luttrell
  • Patent number: 9453841
    Abstract: The present invention concerns a monoclonal antibody and corresponding hybridoma cells and antigens suitable for isolating fetal cells from maternal blood. The inventive monoclonal antibody reacts with a surface antigen present on fetal red blood cells including their nucleated precursor cells, but not with surface antigens on adult erythroid cell.
    Type: Grant
    Filed: October 14, 2015
    Date of Patent: September 27, 2016
    Assignee: KellBenx Inc.
    Inventors: Christiane Hollmann, Silke Zimmermann, Stefan Stachelhaus, Winfried Albert
  • Patent number: 9360433
    Abstract: A system for the indirect detection of agglutination in an agglutination assay using optical density measurement and a reaction vessel. Light emitted by light source is transmitted through reaction vessel containing components of an agglutination reaction that is detected by light detector. As particles in the reaction vessel settle in the absence of agglutination they are concentrated in a reaction vessel lower volume and increase the optical density of the light path through the reaction vessel. Light detector generates an output signal related to said optical density. Said output signal is read and interpreted by an instrument to detect a presence or absence of agglutination. Other embodiments are described and shown.
    Type: Grant
    Filed: May 16, 2014
    Date of Patent: June 7, 2016
    Assignee: InDevR, Inc.
    Inventors: Kathy Lou Rowlen, Jean-Luc Fraikin, John William Birks, Craig J. Williford
  • Patent number: 9327027
    Abstract: The present invention relates to hydroxyapatite doped with Fe2+ ions and Fe3+ ions which partially substitute the calcium ions in the crystal lattice. The hydroxyapatite is characterized by an intrinsic magnetism of 0.05 to 8 emu/g, measured by applying a magnetic field of 34 Oe, due to the presence of magnetic nano-domains in the crystal lattice of HA, given the limited amount of magnetic secondary phases present, less than about 3% by volume. The intrinsically magnetic hydroxyapatite can be loaded with biological substances selected in the group consisting of proteins, genes, stem cells, growth factors, vascularization factors, active substances and drugs, under the control of an external magnetic field, as a carrier and release agent for biological substances or drugs, as a contrast agent in diagnostics or for bone or osteocartilage regeneration.
    Type: Grant
    Filed: July 28, 2011
    Date of Patent: May 3, 2016
    Assignees: CONSIGLIO NAZIONALE DELLE RICERCHE, UNIVERSIDADE DE SANTIAGO DE COMPOSTELA, FIN-CERAMICA FAENZA S.P.A.
    Inventors: Anna Tampieri, Elena Landi, Monica Sandri, Daniele Pressato, José Rivas Rey, Manuel Banobre López, Maurilio Marcacci
  • Patent number: 9321846
    Abstract: Compositions and methods comprising proteins that bind specifically to adalimumab are disclosed herein. Adalimumab is a monoclonal antibody specific for the cytokine TNF-? and was developed to treat TNF-? mediated inflammatory diseases. In one aspect of the instant invention, the binding proteins are antibodies directed toward adalimumab. These antibodies, including binding fragments thereof, can be used in a clinical setting as well as for research and development. For example, these anti-adalimumab antibodies can be employed to neutralize adalimumab.
    Type: Grant
    Filed: February 24, 2015
    Date of Patent: April 26, 2016
    Assignee: ABBVIE BIOTECHNOLOGY LTD.
    Inventors: Zehra Kaymakcalan, Limin Xiong
  • Patent number: 9285365
    Abstract: A method for the enumeration of micronucleated erythrocyte populations while distinguishing platelet and platelet-associated aggregates involves the use of a first fluorescent labeled antibody having binding specificity for a surface marker for reticulocytes, a second fluorescent labeled antibody having binding specificity for a surface marker for platelets, and a nucleic acid staining dye that stains DNA (micronuclei) in erythrocyte populations. Because the fluorescent emission spectra of the first and second fluorescent labeled antibodies do not substantially overlap with one another or with the emission spectra of the nucleic acid staining dye, upon excitation of the labels and dye it is possible to detect the fluorescent emission and light scatter produced by the erythrocyte populations and platelets, and count the number of cells from one or more erythrocyte populations in said sample.
    Type: Grant
    Filed: October 24, 2014
    Date of Patent: March 15, 2016
    Assignee: Litron Laboratories, Ltd.
    Inventor: Stephen D. Dertinger
  • Patent number: 9182389
    Abstract: Detection of the presence or absence of, RH positive cells in a mixed population with Rh negative cells, as is found in a fetal maternal hemorrhage (FMH). The novel methods utilize gravitational forces or applying magnetic forces to reactive magnetic particles to isolate, distinguish and quantify cells. Particles aggregate and are pulled or settle by gravity through a transparent separating solution into a measuring zone where the volume of Rh positive cells can be measured. Rh positive cell volume is correlated to the volume of the original blood sample as an indication of the number of doses of RhIG needed to be administered to the mother to prevent subsequent Rh immunization.
    Type: Grant
    Filed: February 21, 2012
    Date of Patent: November 10, 2015
    Assignee: Chrome Red Technologies, LLC
    Inventors: Henry A. Graham, John G. Gorman, James P. Rowell
  • Patent number: 9125941
    Abstract: The invention discloses an aqueous method of making polymer coated superparamagnetic nanoparticles. Nanoparticles made by the method are included in the invention.
    Type: Grant
    Filed: June 25, 2014
    Date of Patent: September 8, 2015
    Assignee: University of Central Florida Research Foundation, Inc.
    Inventors: Jesus Manuel Perez, Sudip Nath
  • Patent number: 9097644
    Abstract: This invention relates generally to magnetic resonance (MR)-based methods and kits for measuring the viscosity of liquid samples.
    Type: Grant
    Filed: August 15, 2008
    Date of Patent: August 4, 2015
    Assignees: Massachusetts Institute of Technology, The General Hospital Corporation
    Inventors: Lee Josephson, Rui Hong, Michael J. Cima, Ralph Weissleder
  • Patent number: 9063189
    Abstract: A system and method are provided to detect target analytes based on magnetic resonance measurements. Magnetic structures produce distinct magnetic field regions having a size comparable to the analyte. When the analyte is bound in those regions, magnetic resonance signals from the sample are changed, leading to detection of the analyte.
    Type: Grant
    Filed: September 6, 2012
    Date of Patent: June 23, 2015
    Assignee: Menon Biosensors, Inc.
    Inventors: Suresh M. Menon, David E. Newman, Steven C. Chan
  • Patent number: 9057094
    Abstract: A method of testing bacterial cells for antimicrobial susceptibility includes preparing a suspension of the bacterial cells in a non-nutrient medium, mixing with the suspension an antimicrobial, a carbohydrate usable by the bacterial cells, metallic nanoparticles, and a lectin, and incubating the mixture while monitoring a parameter of the nanoparticles responsive to use of the carbohydrate by the bacterial cells. More broadly stated, the invention includes a method of testing an agent for its effect on cell metabolism by preparing a suspension of cells in a non-nutrient medium, mixing the suspension with the agent, adding a carbohydrate usable by the cells, metallic nanoparticles, and a lectin with binding specificity for the added carbohydrate, and monitoring a nanoparticle parameter responsive to the cells.
    Type: Grant
    Filed: October 27, 2008
    Date of Patent: June 16, 2015
    Assignees: UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC., NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS
    Inventors: J. Manuel Perez, Charalambos Kaittanis, Sudip Nath
  • Publication number: 20150140578
    Abstract: Methods and devices for evaluating a sample from a subject for the presence of a mixed population of cells, e.g., a sample having more than one distinct populations of cells, e.g., red blood cells (RBCs). Also included are methods and devices for Coombs crossmatch and DAT testing.
    Type: Application
    Filed: May 28, 2013
    Publication date: May 21, 2015
    Inventor: Daniel M. Mueth
  • Publication number: 20150140579
    Abstract: The invention relates to an in vitro diagnosis device (10) for the detection of at least one reaction between an erythrocytic phenotype antigen and an antibody specifically directed against said antigen in a sample of blood or one of the components thereof. The device is characterised in that it comprises: a substrate (12); and a hydrophobic porous membrane (14) having a thickness of between 0.5 mm and 1.5 mm and a pore diameter of between 2 and 30 ?m, said membrane comprising at least one hydrophilic reaction zone (16) intended to receive the sample. The invention also relates to the uses of said device in immunohematology.
    Type: Application
    Filed: June 11, 2013
    Publication date: May 21, 2015
    Applicant: Abo Diag
    Inventors: Najim Chaibi, Sylvain Malgouries, Megumi Lucas
  • Publication number: 20150140555
    Abstract: There is provided a method for identifying at least one foetal erythroblast the method comprising: (a) detecting the expression of at least one foetal erythroblast specific marker selected from the group consisting of neutral amino acid transporter B (SLC1A5), solute carrier family 3 (activators of dibasic and neutral amino acid transport) member 2 isoform A (SLC3A2), Splice Isoform A of Chloride channel protein 6, Transferrin receptor protein 1, Splice Isoform 3 of Protein GPR107 precursor, Olfactory receptor 11H4, Splice Isoform 1 of Protein C9orf5, Cleft lip and palate transmembrane protein 1, BCG induced integral membrane protein BIGM103, Antibacterial protein FALL-39 precursor, CAAX prenyl protease 1 homolog, Splice Isoform 2 of Synaptophysin-like protein, Vitamin K epoxide reductase complex subunit 1-like protein 1, Splice Isoform 1 of Protein C20orf22 (ABHD12), Hypothetical protein DKFZp564K247 (Hypoxia induced gene 1 protein) (IPI Accession No.
    Type: Application
    Filed: May 23, 2013
    Publication date: May 21, 2015
    Inventors: Mahesh Choolani, Sukumar Ponnusamy, Huoming Zhang, Qingsong Lin, Aniza Puteri Mahyuddin, Priya Kadam
  • Publication number: 20150132403
    Abstract: The present invention provides methods for inhibiting complement activation and uses thereof. More specifically, the present invention provides methods for inhibiting complement activation using polyphosphates.
    Type: Application
    Filed: November 7, 2014
    Publication date: May 14, 2015
    Inventors: Edward CONWAY, Jing Zhou CUI, Jonathan FOLEY, Michael KRISINGER, Joanne MATSUBARA, Linnette OCARIZA, Jovian WAT
  • Publication number: 20150118676
    Abstract: Electrokinetic devices and methods are described with the purpose of collecting assayable agents from a dielectric fluid medium. Electrokinetic flow may be induced by the use of plasma generation at high voltage electrodes and consequent transport of charged particles in an electric voltage gradient. In one embodiment, an ionic propulsion device for providing a sample for a bio-specific assay of aerosol particles comprises a housing receiving a sample of aerosol particles and enclosing a high voltage electrode to generate a plasma of electrically charged particles. A carrier assembly is removably receivable in the housing, the carrier assembly comprising a non-conductive carrier and an electrode removably secured to the carrier.
    Type: Application
    Filed: August 22, 2014
    Publication date: April 30, 2015
    Inventor: Julian Gordon
  • Publication number: 20150111198
    Abstract: A medical analysis method uses a medical analysis machine provided with a poly-articulated robot (70) comprising joints defining at least six axes of rotation (A1, A2, A3, A4, A5, A6) and adapted for spacing and/or orienting a terminal member (66) according to six degrees of freedom, the terminal member bearing a grasping member (78) adapted for grasping a container (16). The medical analysis method comprises at least the succession of steps consisting of providing a container (16) containing a sample to be treated stemming from a human being or an animal, transferring said container (16) towards at least one treatment station of the medical analysis machine (100) by means of the poly-articulated robot, treating the sample in a treatment station, transferring the container towards a station for capturing images, and displaying the treatment results through a user interface.
    Type: Application
    Filed: March 8, 2013
    Publication date: April 23, 2015
    Inventors: Jean-Michel Brisebat, Sébastien Bernay, Cédric Gagnepain, Daniel Seydoux
  • Publication number: 20150111770
    Abstract: This invention relates to determination of quantitative expression of plasma membrane proteins as biomarkers in the erythrocytes. The invention includes simple, quantitative assay platforms which can be made available in most diagnostic laboratories. The platform allows performing personalized, quantitative tests for the direct expression level of a wide range of membrane proteins from small volume blood samples and connecting them to individual genetic variability, disease conditions, disease stages and complications, treatment protocols, pharmacological responses, or toxic side effects.
    Type: Application
    Filed: April 22, 2013
    Publication date: April 23, 2015
    Applicant: AdvanCell Diagnosztika Kft.
    Inventors: Balázs Sarkadi, György Várady, Ildikó Kasza
  • Publication number: 20150098942
    Abstract: OX40 is a potent immune stimulating target. Provided herein are methods for the treatment of cancer patients using (3X40 agonists methods to predict clinical outcome of the treatment by correlation of the treatment and an increase in OX40-induced T cell proliferation.
    Type: Application
    Filed: February 6, 2012
    Publication date: April 9, 2015
    Applicant: Providence Health & Services - Oregon d/b/a Providence Portland Medical Center
    Inventors: Brendan Curti, Magdalena Kovacsovics-Bankowski, Ed Walker, Josh Walker, Andy Weinberg
  • Patent number: 8980568
    Abstract: The present invention recognizes that diagnosis and prognosis of many conditions can depend on the enrichment of rare cells, especially tumor cells, from a complex fluid sample such as a blood sample. In particular, the present invention is directed to methods and compositions for detecting a non-hematopoietic cell, e.g., a non-hematopoietic tumor cell, in a blood sample via, inter alia, removing red blood cells (RBCs) from a blood sample using a non-centrifugation procedure, removing white blood cells (WBCs) from said blood sample to enrich a non-hematopoietic cell, if any, from said blood sample; and assessing the presence, absence and/or amount of said enriched non-hematopoietic cell.
    Type: Grant
    Filed: October 31, 2005
    Date of Patent: March 17, 2015
    Assignee: Aviva Biosciences Corporation
    Inventors: Ping Lin, Douglas T. Yamanishi, Paul G. Hujsak, Sara F. Snyder, George Walker, Junquan Xu, Mingxian Huang, Guoliang Tao, Lei Wu, Xiaobo Wang, Joe Ouyang, Charina Schmitigal, Jing Cheng, Elizabeth Kwok, Jia Xu
  • Publication number: 20150064690
    Abstract: A facile method of localising sulfhydryl (—SH) group containing biomolecules, in particular peptides, to the membranes of living cells and enveloped viruses and a kit for use in a biological laboratory in accordance with the method.
    Type: Application
    Filed: August 31, 2012
    Publication date: March 5, 2015
    Inventors: Nikolai Vladimirovich Bovin, Stephen Micheal Henry
  • Patent number: 8969021
    Abstract: The present invention recognizes that diagnosis and prognosis of many conditions can depend on the enrichment of rare cells, especially tumor cells, from a complex fluid sample such as a blood sample. In particular, the present invention is directed to methods and compositions for detecting a non-hematopoietic cell, e.g., a non-hematopoietic tumor cell, in a blood sample via, inter alia, removing red blood cells (RBCs) from a blood sample using a non-centrifugation procedure, removing white blood cells (WBCs) from said blood sample to enrich a non-hematopoietic cell, if any, from said blood sample; and assessing the presence, absence and/or amount of said enriched non-hematopoietic cell.
    Type: Grant
    Filed: September 13, 2013
    Date of Patent: March 3, 2015
    Assignee: AVIVA Biosciences Corporation
    Inventors: Ping Lin, Douglas T. Yamanishi, George Walker, Junquan Xu, Mingxian Huang, Guoliang Tao, Lei Wu, Xiaobo Wang, Joe Ouyang, Jing Cheng, Jia Xu
  • Patent number: 8956879
    Abstract: An analysis device includes: a separation cavity 18 for separating a test liquid into a solution component and a solid component by using a centrifugal force; a higher specific gravity component quantitative cavity 23 for holding a portion of the separated solid component which has been transferred; a sample solution overflow cavity 22 arranged between the higher specific gravity component quantitative cavity 23 and the separation cavity 18 and connected to a connecting channel 21 for transporting the sample liquid from the separation cavity 18; and a capillary cavity 19 formed in the separation cavity 18 for temporarily holding a separated solution component (blood plasma) in the separation cavity 18. A blood plasma component 57a remaining in the separation cavity 18 is trapped by the capillary cavity 19.
    Type: Grant
    Filed: February 19, 2013
    Date of Patent: February 17, 2015
    Assignee: Panasonic Healthcare Co., Ltd.
    Inventors: Masanori Tanaka, Hirotaka Tanaka, Hiroshi Saiki
  • Patent number: 8945857
    Abstract: The invention provides methods for isolating cells, particularly antibody-secreting cells that have a high likelihood of secreting antibodies specific for a desired antigen for the purpose of making monoclonal antibodies.
    Type: Grant
    Filed: June 30, 2006
    Date of Patent: February 3, 2015
    Inventor: John Schrader
  • Patent number: 8940495
    Abstract: Disclosed herein is a lateral flow immuno-assay system capable of rapidly, cost effectively, and quantitatively detecting and assessing the level of HIT antibodies in body fluids of a patient. Also taught are methods for employing the system to assist in diagnosis of HIT, and for screening or detecting a changing titer of HIT antibodies in the body fluids of a patient to determine susceptibility toward HIT.
    Type: Grant
    Filed: February 26, 2009
    Date of Patent: January 27, 2015
    Assignee: BioMedomics, Inc
    Inventors: Xue-feng Wang, Xuejie Wang
  • Publication number: 20150024413
    Abstract: The present invention relates to a method for detecting cardiovascular oxidative stress in an individual, comprising detecting in a blood sample from the individual modification of a cysteine at position 45 of the ?1-subunit of the human erythrocyte ATP-dependent Na+K+ pump protein or of an equivalent cysteine in a homologue or variant thereof. The invention further relates to a kit for detecting cardiovascular oxidative stress in an individual, the kit comprising at least one agent for detecting the presence of a modification in a cysteine at position 45 of the ?1-subunit of the human erythrocyte ATP-dependent Na+K+ pump protein or of an equivalent cysteine in a homologue or variant thereof, wherein said modification is a result of oxidation.
    Type: Application
    Filed: November 1, 2013
    Publication date: January 22, 2015
    Applicants: The University of Sydney, Northern Sydney Local Health District
    Inventors: Gemma Alexandra Figtree, Chia-Chi Liu, Natasha Alexandria Sarah Fry, Keyvan Karimi Galougahi
  • Publication number: 20140371090
    Abstract: A method and kit for determining antibody sensitivity and quality of a clone cell stain. The method comprises: obtaining a solid-phase carrier, cells and an antibody; adsorbing the antibody on the solid-phase carrier; incubating the cells and the antibody; preserving cells bound with the antibody; and dyeing and counting the cells bound with the antibody, so as to determine the antibody sensitivity or the quality of the clone cell stain based on the cell count. The kit comprises components used in the method.
    Type: Application
    Filed: June 30, 2014
    Publication date: December 18, 2014
    Inventors: Yumei Zhao, Lifang Dong, Ting Lei
  • Publication number: 20140370525
    Abstract: Methods for detecting and/or imaging erythrocyte precursor cells are provided.
    Type: Application
    Filed: October 18, 2012
    Publication date: December 18, 2014
    Applicant: The Children's Hospital of Philadelphia
    Inventors: Mitchell Weiss, John Kim Choi
  • Publication number: 20140363827
    Abstract: An apparatus and a method for identifying the characteristics of a liquid sample due to capillary force are disclosed. The apparatus and the method spread the blood sample (which is obtained from the blood of a subject, or a mixture containing the blood of two different subjects) having an agglutination portion in a distribution space due to the capillary force.
    Type: Application
    Filed: June 5, 2014
    Publication date: December 11, 2014
    Inventors: Shu-Hsien Liao, Chuan-Fa Chang, Hsien Chang Chang
  • Publication number: 20140363828
    Abstract: An assaying kit is for pre-transfusion blood group matching between two blood samples. The kit includes at least two assemblies (101,201) corresponding to the first and the second blood sample, each assembly has at least two test units (1). Each test unit (1) includes a reagent containing an antigen present on erythrocytes or an antibody able to bind to an antigen present on erythrocytes. Each test unit (1) also includes a membrane (2) permeable to free erythrocytes (6) and impermeable to hemagglutinated erythrocytes. The antibody contained in the first test unit for both the first assembly (101) and the second assembly (201) corresponds to a first blood group and the antibody contained in the second test units for both the first assembly (101) and the second assembly (201) corresponds to a second blood group.
    Type: Application
    Filed: December 5, 2012
    Publication date: December 11, 2014
    Applicant: UNIVERSITE LIBRE DE BRUXELLES
    Inventors: Francis Corazza, Hanane El Kenz
  • Publication number: 20140341892
    Abstract: The invention relates to anti-?2 integrin antibodies and their uses. Humanized antibodies are disclosed that bind to the I domain of ?2 integrin and inhibit the interaction of ?2?1 integrin with collagen. Also disclosed are therapeutic uses of anti-?2 integrin antibodies in treating ?2?1-mediated disorders, including anti-?2 integrin antibodies that bind to ?2 integrin without activating platelets.
    Type: Application
    Filed: May 19, 2014
    Publication date: November 20, 2014
    Applicant: GLENMARK PHARMACEUTICALS S.A.
    Inventors: Elias LAZARIDES, Catherine Woods, Mark Bernard
  • Patent number: 8889365
    Abstract: The present inventions relates to kits and methods for diagnosing and monitoring breast cancer. An increase in the level or activity of proteins of the ubiquitin/proteasome pathway, and ancillary proteins thereof, as compared to normal control or benign tissue is indicative of breast cancer.
    Type: Grant
    Filed: August 8, 2011
    Date of Patent: November 18, 2014
    Assignee: Rutgers, The State University of New Jersey
    Inventors: Kiran Madura, Li Chen
  • Patent number: 8889368
    Abstract: The invention relates to a method for phenotyping blood and/or performing an irregular agglutinin test and/or for determination of compatibility of a donor and receiver, using an aqueous solution of ferrofluid, obtained from a mixture of polyoxoanions of Fe(III) and at least one metal M(II) of oxidation state II. The invention further relates to a kit for carrying out said procedure.
    Type: Grant
    Filed: May 3, 2005
    Date of Patent: November 18, 2014
    Assignee: Diagast
    Inventors: Yves Barbreau, Olivier Boulet, Arnaud Boulet, Alexis Delanoe, Laurence Fauconnier, Jean-Marc Pelosin, Laurent Soufflet
  • Patent number: 8889369
    Abstract: A method for the enumeration of micronucleated erythrocyte populations while distinguishing platelet and platelet-associated aggregates involves the use of a first fluorescent labeled antibody having binding specificity for a surface marker for reticulocytes, a second fluorescent labeled antibody having binding specificity for a surface marker for platelets, and a nucleic acid staining dye that stains DNA (micronuclei) in erythrocyte populations. Because the fluorescent emission spectra of the first and second fluorescent labeled antibodies do not substantially overlap with one another or with the emission spectra of the nucleic acid staining dye, upon excitation of the labels and dye it is possible to detect the fluorescent emission and light scatter produced by the erythrocyte populations and platelets, and count the number of cells from one or more erythrocyte populations in said sample.
    Type: Grant
    Filed: November 8, 2013
    Date of Patent: November 18, 2014
    Assignee: Litron Laboratories, Ltd.
    Inventor: Stephen D. Dertinger
  • Publication number: 20140315748
    Abstract: The invention provides a method for isolating or enriching a rare cell from a biological fluid of a mammal employing an antibody that binds a cell-surface antigen of the rare cell. The immobilized antibody is incubated with a sample of biological fluid that includes the rare cells and a plurality of other cells so as to form an antibody-rare cell complex. The complex can be detected or isolated and subsequently analyzed by any of a variety of physical, chemical and genetic techniques.
    Type: Application
    Filed: November 13, 2012
    Publication date: October 23, 2014
    Inventors: Javad Khosravi, Leonard H. Kellner, Hassan Bennani
  • Patent number: 8841082
    Abstract: The invention relates to a method for determining one or more cellularly bound analytes in a liquid sample, said method being carried out using a device comprising: at least one feeding zone (5) for applying the liquid sample; a porous membrane (2) that is suitable for letting cellular components penetrate therethrough and includes at least one indicator zone on the membrane, said indicator zone being able to interact with the cellularly bound analyte and containing at least one binding element against the cellularly bound analyte; and at least one absorption area (3) on the membrane, which absorbs the liquid after the liquid has passed the indicator zones. The at least one indicator zone lies between the feeding zone (5) and the absorption area (3).
    Type: Grant
    Filed: December 14, 2007
    Date of Patent: September 23, 2014
    Assignee: Medion Diagnostics AG
    Inventors: Peter Schwind, Iwan Aebischer
  • Patent number: 8828737
    Abstract: Methods for using focused light scattering techniques for the optical sensing of biological particles suspended in a liquid medium are disclosed. The optical sensing enables one to characterize particles size and/or distribution in a given sample. This, in turn, allows one to identify the biological particles, determine their relative particle density, detect particle shedding, and identify particle aggregation. The methods are also useful in screening and optimizing drug candidates, evaluating the efficacy and dosage levels of such drugs, and in personalized medicine applications.
    Type: Grant
    Filed: July 14, 2009
    Date of Patent: September 9, 2014
    Assignee: Invitrox, Inc.
    Inventor: Don Gabriel
  • Patent number: 8802385
    Abstract: The present invention relates to a new suspension medium or diluent solution for red blood cells for use in haematological methods. The suspension medium or diluent solution for red blood cells may comprise a combination of two or more amino acids of any group, and preserves the red blood cells in the sample for at least 8 weeks.
    Type: Grant
    Filed: June 22, 2007
    Date of Patent: August 12, 2014
    Assignee: Grifols, S.A.
    Inventors: Daniel Martorell Pena, Ma del Carmen Traves Polo, Jordi Farre Leon, Josefina Castells Parera
  • Publication number: 20140206019
    Abstract: The present invention discloses a method of assaying Fc-function in an immunoglobulin containing sample by contacting the sample, in the presence of a complement, with red blood cells modified to incorporate a F-S-L peptide-lipid construct. The F-S-L peptide construct comprises a functional group (F) that is a target antigen for a complement activating immunoglobulin, a spacer group (S) covalently linking F to L and a lipid group (L). The present invention further discloses a specific construct, DOPE-Ad-CMG(2)-hCMV2 where the F group is an antigen of cytomegalovirus, that is used in assaying the Fc function of an intravenous immunoglobulin (IVIG) product.
    Type: Application
    Filed: March 5, 2012
    Publication date: July 24, 2014
    Applicant: Kode Biotech Limited
    Inventors: Stephen Micheal Henry, Venkata Sarvani Komarraju
  • Publication number: 20140154704
    Abstract: The present invention concerns a monoclonal antibody and corresponding hybridoma cells and antigens suitable for isolating fetal cells from maternal blood. The inventive monoclonal antibody reacts with a surface antigen present on fetal red blood cells including their nucleated precursor cells, but not with surface antigens on adult erythroid cell.
    Type: Application
    Filed: September 16, 2013
    Publication date: June 5, 2014
    Applicant: Adnagen AG
    Inventors: Christiane Hollmann, Silke Zimmermann, Stefan Stachelhaus, Winfried Albert
  • Publication number: 20140141997
    Abstract: In one aspect, the invention is directed to methods of separating foetal nucleated red blood cells (FNRBCs) from a sample comprising contacting the sample with an agent that specifically recognizes CD147, thereby producing a mixture; maintaining the mixture under conditions in which a complex forms between the agent and the CD147 in the sample; and separating the complex from the mixture; thereby separating the FNRBCs from the sample. In other embodiments, the invention is directed to methods of detecting FNRBCs in a sample comprising contacting the sample with an antibody or antigen binding fragment thereof that specifically binds CD147, thereby producing a combination; maintaining the combination under conditions in which an immune complex forms between the antibody and FNRBCs present in the sample; and detecting whether the immune complex forms in the combination; wherein if the immune complex is detected then FNRBCs are present in the sample.
    Type: Application
    Filed: June 28, 2012
    Publication date: May 22, 2014
    Applicant: NATIONAL UNIVERSITY OF SINGAPORE
    Inventors: Aniza Puteri Mahyuddin, Sukumar Ponnusamy, Priya Kadam, Mahesh Choolani
  • Publication number: 20140134648
    Abstract: Methods of determining health status based on analysis of single cells in a sample or set of samples from an individual are described.
    Type: Application
    Filed: October 3, 2013
    Publication date: May 15, 2014
    Applicant: NODALITY, INC.
    Inventors: Wendy J. Fantl, Helen L. Francis-Lang, Aileen C. Cohen, Garry P. Nolan
  • Patent number: 8691515
    Abstract: Disclosed herein are methods of detecting blood disorders, such as diabetes. In particular examples the method includes contacting a blood sample with an amine reagent, blocking an excess of the amine reagent with a blocking reagent, digesting the modified blood sample with trypsin to produce a digested blood sample containing a plurality of glycated N-terminal peptides and non-glycated N-terminal peptides, then analyzing the digested blood sample with MALDI MS. Also provided are reagents for use in such methods.
    Type: Grant
    Filed: July 7, 2010
    Date of Patent: April 8, 2014
    Assignee: UVic Industry Partnerships Inc.
    Inventors: Evgeniy V. Petrotchenko, Christoph Borchers
  • Publication number: 20140093540
    Abstract: Immunogenic compositions and vaccines against Plasmodial infection comprising an Rh polypeptide or a fragment or variant thereof are disclosed. Also disclosed are Rh5 polypeptides or fragments or variants thereof capable of binding CD147 and conferring protection against infection and/or disease caused by multiple Plasmodial strains or Plasmodial species, inhibitors of the interaction between Rh5 and CD147 and methods for producing polypeptides in a mammalian expression system.
    Type: Application
    Filed: October 7, 2011
    Publication date: April 3, 2014
    Applicant: Genome Research Limited
    Inventors: Gavin J. Wright, Julian C. Rayner, Cecile Crosner, Leyla Y. Bustamante, S. Josefin Bartholdson